Active substance
Sodium picosulfate
- SFDA 2
- NHS prices 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PICO 7.5MG-ML ORAL DROPS | 7.5 mg/ml | Oral drops · Oral use | 1 Dropper Container | SAR 12.00 | Generic · OTC | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| SKILAX DROPS | 7.5 mg/ml | Oral drops, solution · Oral use | 1 Bottle | SAR 4.65 | Generic · Prescription | ALMIRALL PRODES PHARMA S.A. | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CONSTIPATION; HEMORRHOIDS
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Sodium picosulfate 5mg/5ml oral solution sugar free | £14.76 | 300 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Aug 2023 CLENPIQ — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Aug 2023 PREPOPIK — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Sodium picosulfate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.